Why AbbVie’s Legal Strategy is Bad for Patients –

[ad_1] AbbVie announced it has settled litigation with generic manufacturers in a way that effectively keeps competition for its blockbuster immunology drug Rinvoq off the market until 2037. Let that sink in: patients, payers, and the healthcare system will be forced to pay monopoly prices for another 12 years—not because of scientific innovation, but because of legal…

Read More